Rapamune
( DrugBank: - / KEGG DRUG: - )
7 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 60 | Aplastic anemia | 5 |
| 66 | IgA nephropathy | 1 |
| 67 | Polycystic kidney disease | 6 |
| 84 | Sarcoidosis | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 158 | Tuberous sclerosis | 6 |
| 278 | Huge lymphatic malformation with cervicofacial lesion | 2 |
| 280 | Huge arteriovenous malformation with cervicofacial or limb lesion | 3 |
60. Aplastic anemia
Clinical trials : 305 / Drugs : 328 - (DrugBank : 91) / Drug target genes : 60 - Drug target pathways : 183
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
66. IgA nephropathy
Clinical trials : 349 / Drugs : 251 - (DrugBank : 75) / Drug target genes : 43 - Drug target pathways : 152
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
67. Polycystic kidney disease
Clinical trials : 233 / Drugs : 188 - (DrugBank : 54) / Drug target genes : 60 - Drug target pathways : 165
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
84. Sarcoidosis
Clinical trials : 175 / Drugs : 189 - (DrugBank : 80) / Drug target genes : 74 - Drug target pathways : 177
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
158. Tuberous sclerosis
Clinical trials : 129 / Drugs : 56 - (DrugBank : 20) / Drug target genes : 35 - Drug target pathways : 116
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
278. Huge lymphatic malformation with cervicofacial lesion
Clinical trials : 32 / Drugs : 32 - (DrugBank : 12) / Drug target genes : 8 - Drug target pathways : 136
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
280. Huge arteriovenous malformation with cervicofacial or limb lesion
Clinical trials : 29 / Drugs : 31 - (DrugBank : 15) / Drug target genes : 12 - Drug target pathways : 163
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|